Core Viewpoint - Guoen Co., Ltd. has successfully passed the main board listing hearing at the Hong Kong Stock Exchange, moving closer to achieving its "A+H" dual listing strategy [1] Company Overview - Guoen Co., Ltd. was established in 2000 with a registered capital of 271 million RMB and is based in Qingdao, Shandong Province. The company was listed on the Shenzhen Stock Exchange in 2015 [1] - The company focuses on technological innovation and aims for long-term scale efficiency, operating in the large chemical and health sectors. It has developed a vertically integrated industrial platform and has diversified into various chemical new materials [1] - Guoen Co. has a controlling stake in Dongbao Biological (300239.SZ), which operates in the health sector, offering products such as gelatin, collagen, and dietary fibers [1] Financial Performance - Guoen Co. reported revenues of 134 billion RMB, 174.4 billion RMB, and 191.9 billion RMB for the fiscal years 2022, 2023, and 2024, respectively. The net profits for the same years were 720 million RMB, 540 million RMB, and 720 million RMB, with a compound annual growth rate (CAGR) of 19.6% [2] - For the first ten months of 2025, the company achieved revenues of 174.4 billion RMB and a gross profit of 18.1 billion RMB [2] Market Outlook - The market for modified and composite materials in China is expected to exceed one trillion RMB from 2025 to 2029. The collagen market is projected to reach 246.2 billion RMB by 2029 [3] Strategic Initiatives - The listing on the Hong Kong Stock Exchange aims to enhance the company's global strategic layout and create an international capital operation platform [3] - Guoen Co. plans to establish a regional headquarters in Hong Kong to support its international operations and supply chain expansion [6] - The company intends to use the funds raised from the listing for establishing a production base in Thailand, expanding production capacity in Yixing, and upgrading its Hong Kong production base [6]

Core Viewpoint - Guoen Co., Ltd. has officially passed the listing hearing on the Hong Kong Stock Exchange, moving closer to achieving its "A+H" dual listing strategy [1] Company Overview - Guoen Co., Ltd. was established in 2000 with a registered capital of 271 million yuan and is based in Qingdao, Shandong Province. The company was listed on the Shenzhen Stock Exchange in 2015 [1] - The company focuses on technological innovation and aims for long-term scale efficiency, operating in the large chemical and health sectors. It has developed a vertically integrated industrial platform and has diversified into various chemical new materials [1][3] - Guoen Co., Ltd. controls Dongbao Biological (300239.SZ), which operates in the health sector, offering products such as gelatin, collagen, and dietary fibers [1] Financial Performance - Guoen Co., Ltd. reported revenues of 13.406 billion yuan, 17.438 billion yuan, and 19.187 billion yuan for the fiscal years 2022, 2023, and 2024, respectively. The net profits for the same years were 720 million yuan, 540 million yuan, and 720 million yuan, with a compound annual growth rate (CAGR) of 19.6% [2] - For the first ten months of 2025, the company achieved revenues of 17.443 billion yuan and a gross profit of 1.81 billion yuan [2] Market Outlook - The market for modified and composite materials in China is expected to exceed one trillion yuan from 2025 to 2029. The collagen market is projected to reach 246.2 billion yuan by 2029 [3] Strategic Initiatives - The company aims to establish a regional headquarters in Hong Kong to support its global strategy and enhance its international operations [6] - The funds raised from the listing will be used for establishing a production base in Thailand, expanding production capacity in Yixing, upgrading the Hong Kong production base, and general corporate purposes [6]